SNY's MS Drug Meets Goal in One Phase III Study; Misses in Two Others
https://www.zacks.com/stock/news/2330244/sny-s-ms-drug-meets-goal-in-one-phase-iii-study-misses-in-two-others?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2330244
Sep 02, 2024 - Sanofi's HERCULES phase III study on tolebrutinib meets primary endpoint, showing an improvement in delaying time to onset of confirmed disability progression.
0
2 No-Brainer Growth Stocks to Buy With $1,000 Right Now
https://www.fool.com/investing/2024/09/01/2-no-brainer-growth-stocks-to-buy-with-1000-right/?source=iedfolrf0000001
Sep 01, 2024 - These disruptive stocks could reap generous rewards for long-term investors.
0
These 3 Factors Could Make Eli Lilly Stock a Better Buy Than Novo Nordisk Right Now
https://www.fool.com/investing/2024/08/31/these-3-factors-could-make-eli-lilly-stock-better-/?source=iedfolrf0000001
Aug 31, 2024 - This competitive showdown just saw one of the players hit a couple of bumps.
0
Pharma Stock Roundup: LLY Offers Cheap Zepbound, EU Okays Some Drugs
https://www.zacks.com/stock/news/2329707/pharma-stock-roundup-lly-offers-cheap-zepbound-eu-okays-some-drugs?cid=CS-ZC-FT-analyst_blog|stock_roundup-2329707
Aug 30, 2024 - LLY launches a discounted version of Zepbound. European Commission approves JNJ's Balversa, MRK's Winrevair and RHHBY's PiaSky.
0
Think Eli Lilly Stock Has Peaked? These 10 Words From the CEO May Change Your Mind
https://www.fool.com/investing/2024/08/30/think-eli-lilly-stock-has-peaked-these-10-words/?source=iedfolrf0000001
Aug 30, 2024 - Eli Lilly may not be an expensive stock when you consider its long-run growth prospects.
0
Lilly (LLY) Is Considered a Good Investment by Brokers: Is That True?
https://www.zacks.com/stock/news/2328857/lilly-lly-is-considered-a-good-investment-by-brokers-is-that-true?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2328857
Aug 29, 2024 - Based on the average brokerage recommendation (ABR), Lilly (LLY) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
0
GSK Stock Gains 18.5% Year to Date: Time to Buy, Sell or Hold?
https://www.zacks.com/stock/news/2328811/gsk-stock-gains-18-5-year-to-date-time-to-buy-sell-or-hold?cid=CS-ZC-FT-analyst_blog|rank_focused-2328811
Aug 29, 2024 - GSK's cheap valuation, reasonable stock price appreciation and bright growth potential indicate that investors should stay invested.
0
Pfizer Follows Lilly's Example, Unveils DTC Service for Selling Drugs
https://www.zacks.com/stock/news/2328497/pfizer-follows-lilly-s-example-unveils-dtc-service-for-selling-drugs?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2328497
Aug 28, 2024 - PFE's digital pharmacy aims to provide patients easy access to its medicines for COVID-19, migraine and other conditions.
0
Roche Obtains Approval For its Rare Blood Disorder Drug in the EU
https://www.zacks.com/stock/news/2327876/roche-obtains-approval-for-its-rare-blood-disorder-drug-in-the-eu?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2327876
Aug 27, 2024 - RHHBY gets approval for PiaSky for treating patients suffering from paroxysmal nocturnal hemoglobinuria in the EU.
0
Merck Stock Worth Watching on PAH Drug Winrevair's Approval in Europe?
https://www.zacks.com/stock/news/2327685/merck-stock-worth-watching-on-pah-drug-winrevair-s-approval-in-europe?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2327685
Aug 27, 2024 - MRK's Winrevair becomes the first novel activin signaling inhibitor therapy approved in Europe to treat PAH.
0